Management of HIV Infection
Management of HIV Infection
Management of HIV Infection
Prevention
These are as follows :1. Sexual contact 2. Exposure to infected body fluids 3. Mother-to-child transmission (MTCT)
It is bad enough that people are dying of AIDS, but no one should die of ignorance.
Prevention
1. Sexual contact :-
Prevention
2. Exposure to infected body fluids
* Fill the syringe with undiluted bleach and wait at least 30 * thoroughly rinse with water * Do this between each persons use
Prevention
3. Mother-to-child transmission (MTCT)
Current recommendations state that when replacement feeding is acceptable, feasible, affordable, sustainable and safe, HIV-infected mothers should avoid breast-feeding their infant. However, if this is not the case, exclusive breast-feeding is recommended during the first months of life and discontinued as soon as possible.t should be noted that women may breastfeed other children who are not their own.
Treatment
HAART: Highly Affective Anti-Retro Viral Therapy: Anti-retro viral therapy is recommended if: Patient is asymptomatic/ symptomatic + CD4 count of <350/l / any AIDS defining condition / plasma HIV RNA greater than 100,000 copies/ml
* HIV ELISA positive, confirmed with Western blot * HIV RNA >55,000 copies/ml * CD4 <350 cells/mm3 * Special considerations:
* Pregnant women * Acute HIV infection * Exposed healthcare workers
Treatment
*RTIs (Nucleoside Reverse Transcriptase Inhibitors):
Zidovudine (AZT/ZDV), Didanosine (DDI), Zalcitabine (DDC), Stavudine (D4T), Lamivudine (3TC)
Treatment
Treatment
For needle stick: Postexposure Prophylaxis ZDV+3TC 28 days, but in high risk (high viral RNA copies)
combination of ZDV+3TC+Indinavir a
Pregnancy: ZDV full dose, trimester 2 and 3+ 6 weeks to neonate reduces vertical
transmission by 80%
Symptomatic tx
and antibiotics/antivirals/glucocorticoids/thalidomide /antifungals/metronidazole for bacterial, viral, autoimmune, fungal and parasitic infections.
HIV/AIDS
22-12
A..Abstain/delay sexual debut BBe faithful/partner reduction CUse Condoms Plus Male Circumcision Avoid illicit Drug use Empower women (educationally/economically) Increase male/youths involvement Prevent MTCT Identify and treat STIs
HIV/AIDS
22-13
Abstinence: Increasing Proportion of Primary 7 School Pupils Delaying Sexual Debut in Soroti District, Uganda, 1994-2001
100 90
80 70
% Change
60 50 40 30 20 10 0
Boys
1994 1996 2001
Girls
HIV/AIDS
Being faithful: Decline in % Reporting Multiple Sex Partners in Uganda (Zero-Grazing Strategy)
40 35 30 25 Percent 20 15 10 5 0 1989 1995 2000
Source: Daniel Halperins 2002 MAQ Mini-university Lecture. HIV/AIDS
Male Female
22-15
Use of Condoms
The only effective FP
method to prevent HIV/STI transmission and acquisition is the condom Male and female condoms are available over the counter Clients should be instructed in proper use Consistent use must be emphasized
HIV/AIDS
Male Condom
Female Condom
22-16
Dual Protection
Dual Protection means protection against
Pregnancy and HIV/STDs. Approaches include: Condom use alone* Condom use and another contraceptive method Mutual monogamy and another FP method Abstinence/delay Avoidance of all penetrative sex
* In typical users, condoms are 80-90% effective in protecting against HIV and STDs and 86% effective in preventing pregnancy. However, if condoms are used correctly and consistently with every act of sex, they are very effective, providing 98% protection against HIV and STD infection and 95-97% protection against pregnancy.
HIV/AIDS
22-17
intercourse Multiple sexual partners Commercial sex work Alcohol abuse Drug abuse Presence of one increases risk of the other
HIV/AIDS
22-18
Tanzania led to a 42% reduction in HIV incidence over a 2-year period Treatment of cervicitis in Mombasa, Kenya, led to a 72% decrease in HIV-1 RNA shedding, thereby reducing infectivity of sero-positive women Recent meta-analysis of 4 randomized controlled trials, however, have NOT shown a positive impact of community-based STI treatment on HIV prevalence. Further randomized controlled trials are needed to test the effect of alternative STI control strategies
Source: Grosskurth et al 1995; McClelland RS et al, 2001; Wilkinson D et al 2002. HIV/AIDS
22-19
Male Circumcision
Conclusions Meta-analysis of 38 observational studies suggest that MC protects against HIV infection Although randomized clinical trials (RCTs) needed to validate this relationship are being conducted in 3 countries, this should not delay the initiation of SAFE (safety, acceptability, feasibility and program effectiveness) studies in selected countries
HIV/AIDS
22-20
equipment Unprotected sexual intercourse (often triggered by alcohol/drug use) Use of contamination equipment for skin-piercing procedures (e.g., tattooing, ear and nose rings) Contamination of drug solutions during production
HIV/AIDS
22-22
users can be reduced through communitybased peer outreaches that are linked to:
Information, education and communication
(IEC) programs for high-risk groups Risk reduction counseling for injection and sexual behavior change Increased access to sterile injecting equipment Increased access to drug dependence treatment
HIV/AIDS
22-23
malnutrition, malaria, parasitic infestation, pregnancyrelated anemia) promptly Minimize unnecessary transfusions: Use blood substitutes (crystalloid/colloid) for volume replacement when possible Select blood donors carefully: Paid or professional donors are a higher risk Create a national blood transfusion service Screen blood supply (and body organs and tissue earmarked for transplantation)
HIV/AIDS
22-24
Infection Prevention
Personal protective
equipment Hand washing Needle and sharps handling and disposal Disinfection of instruments Appropriate disposal of tissues and other contaminated items HBV immunization
HIV/AIDS
22-25
22-27
with soap and water and rinse thoroughly to remove all potentially infectious particles. Cut or punctured skin: allow to bleed fully. Eye: flush immediately with water, then irrigate with normal saline for 30 minutes. Consider post exposure prophylaxis (PEP) if high risk of transmission:
4 week course of zidovudine (ZDV) preferable to start within 1-2 hours
Source: CDC 1996. HIV/AIDS
22-28
months Treatment, if started, should continue for 4 weeks. Any or all drugs may be declined by exposed worker. For lesser exposures, prophylaxis is not recommended.
HIV/AIDS
22-29